Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 8Primary Myelofibrosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Thrombocythemia, Essential 4Recurrence 4Polycythemia Vera 4Multiple Myeloma 4Lymphoma, T-Cell 4Leukemia 4Lymphoma, T-Cell, Cutaneous 3Graft vs Host Disease 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Large Granular Lymphocytic 2Hematologic Neoplasms 2Triple Negative Breast Neoplasms 1Targeted Therapy 1Prostatic Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

pembrolizumab 57Carboplatin 34Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16Specimen Handling 15130-nm albumin-bound paclitaxel 15toripalimab 11Drug Therapy 11Biopsy 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × ruxolitinib × Clear all
NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Baylor Research Institute

Phase EARLY_PHASE1 Recruiting
20 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡